Advertisement

Cardiovascular risk factors’ behavior during the early stages of the disease, in Hispanic rheumatoid arthritis patients: a cohort study

  • Irazú Contreras-Yáñez
  • Guillermo Guaracha-Basáñez
  • Virginia Pascual-RamosEmail author
Comorbidities
  • 24 Downloads

Abstract

Rheumatoid arthritis (RA) patients from Latin America present distinctive characteristics relevant when assessing their cardiovascular (CV) risk. The objective was to monitor CV risk factor behavior in the early stages of the disease and to identify predictors of major CV outcomes (MACE). A recent-onset RA cohort was initiated in 2004; data from 185 patients with ≥ 1 year of follow-up were analyzed. Patients underwent prospective assessments of CV risk factors. Incident MACE were confirmed according to standardized definitions. Appropriated statics was used based on the distribution of the variables. At baseline, patients were primarily middle-aged females (87.6%), with active disease (69.7%). Most prevalent CV risk factors were C-reactive-protein > 1 mg/L (90.3%), Castelli ratio > 3 (83.8%), and low–high-density lipoprotein levels (73.5%). The number of patients with an incident CV risk factor after 1 year was higher for a Castelli ratio > 3 (23%), low–high-density lipoprotein serum cholesterol (16.3%), high total serum cholesterol (10.6%), and BMI ≥ 30 kg/m2 (10%). A minority of patients met the age-range criteria for the application of ACC/AHA 2013 criteria and Reynolds Risk Score (45.8% and 34.1%, respectively). Fifteen patients were classified with high-CV risk during the first year of follow-up, according to ACC/AHA 2013 criteria. Until June 2018, the cohort underwent 1358 patient/years follow-up; six patients developed incidental MACE; high-CV risk at baseline failed to predict MACE. Recent-onset RA Hispanic patients present a distinctive pattern and first-year behavior of CV risk factors. During follow-up, few patients developed incidental MACE.

Keywords

Cardiovascular diseases Risk factors Rheumatoid arthritis 

Notes

Author contributions

ICY: she participated in the conception and design of the study; she performed the statistical analysis; she is in charge of databases integrity of the early arthritis clinic; GGB: he participated in the conception and design of the study, he performed patient´s charts evaluations, and he reviewed the manuscript; VPR: she participated in the conception and design of the study, performed patient´s clinical evaluations; performed the statistical analysis, and drafted the manuscript; in charge of the early arthritis clinic.

Funding

This study was not funded.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures performed this study were in accordance with the ethical standards of the Institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

296_2019_4451_MOESM1_ESM.docx (12 kb)
Supplementary material 1 (DOCX 12 kb)

References

  1. 1.
    Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile J, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheumatol 59:1690–1697CrossRefGoogle Scholar
  2. 2.
    Choy E, Ganeshalingam K, Semb AG, Szekanecz Z, Numohamed M (2014) Cardiovascular risk in rheumatoid arthritis: recent advances in in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) 53:2143–2154CrossRefGoogle Scholar
  3. 3.
    Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated to rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69:1920–1925CrossRefGoogle Scholar
  4. 4.
    Innala L, Möller B, Ljung L et al (2011) Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a 5 year prospective study. Arthritis Res Ther 13:R131CrossRefGoogle Scholar
  5. 5.
    Symmons DP, Gabriel SE (2011) Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 7:399–408CrossRefGoogle Scholar
  6. 6.
    Agca R, Heslinga SC, Rollefstad S et al (2017) EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 76:17–28CrossRefGoogle Scholar
  7. 7.
    Mody GM, Cardiel MH (2008) Challenges in the management of rheumatoid arthritis in developing countries. Best Pract Clin Rheumatol 22:621–641CrossRefGoogle Scholar
  8. 8.
    Parra-Salcedo F, Contreras-Yáñez I, Elías-López D, Aguilar-Salinas CA, Pascual-Ramos V (2015) Prevalence, incidence, and characteristics of the metabolic syndrome (Mets) in a cohort of Mexican mestizos early rheumatoid arthritis patients treated with conventional disease modifying anti-rheumatic drugs: the complex relationship between metabolic syndrome and disease activity. Arthritis Res Ther 1:17–34Google Scholar
  9. 9.
    Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R (2010) Prevalence of dyslipidaemias in the Mexican National Health and Nutrition Survey 2006. Salud Pub Mex 52(Suppl 52):S44–S53CrossRefGoogle Scholar
  10. 10.
    Aguilar-Salinas CA, Canizales-Quinteros S, Rojas-Martínez R et al (2009) Hypoalphalipoproteinemia in populations of native American ancestry: an opportunity to assess the interaction of genes and the environment. Currr Opin Lipidol 20:92–97CrossRefGoogle Scholar
  11. 11.
    Sánchez T, Elías-López D, Contreras-Yáñez I, Aguilar-Salinas C, Pascual-Ramos V (2014) Prevalence of lipid phenotypes, serum lipid’s behavior over follow-up and predictors of serum lipid levels in a cohort of Mexican mestizos early rheumatoid arthritis (RA) patients treated with conventional DMARDs. Clin Exp Rheumatol 32:509–515PubMedGoogle Scholar
  12. 12.
    ENSANUT (2016) Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. ENSANUT 2016:1–154Google Scholar
  13. 13.
    Stavropolous-Kalinoglou A, Metsios GS, Koutedakis Y et al (2007) Redefining overweight and obesity in rheumatoid arthritis. Ann Rheum Dis 66:1316–1321CrossRefGoogle Scholar
  14. 14.
    Sarmiento-Monroy JC, Amaya-Amaya J, Espinosa-Serna JS, Herrera-Díaz C, Anaya JM, Rojas-Villarraga A (2012) Cardiovascular disease in rheumatoid arthritis: a systematic literature review in Latin America. Arthritis 1:1–17CrossRefGoogle Scholar
  15. 15.
    Galarza-Delgado DA, Azpiri-López JR, Colunga-Pedraza IJ et al (2017) Assessment of six cardiovascular risk calculators in Mexican mestizo patients with rheumatoid arthritis according to the EULAR 2015/2016 recommendations for cardiovascular risk management. Clin Rheumatol 6:1387–1393CrossRefGoogle Scholar
  16. 16.
    Rannio T, Asikainen J, Kokko A, Hannonen P, Sokka T (2016) Early remission is a realistic target in a majority of patients with DMARD-naïve. J Rheumatol 43:699–706CrossRefGoogle Scholar
  17. 17.
    Contreras-Yáñez I, Pascual-Ramos V (2015) Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters. Arthritis Res Ther 17:177CrossRefGoogle Scholar
  18. 18.
    Panoulas VF, Mestios GS, Pace AV et al (2008) Hypertension in rheumatoid arthritis. Rheumatology 47:1286–1298CrossRefGoogle Scholar
  19. 19.
    Primdahl J, Clausen J, Hørslev-Petersen K (2013) Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations. Ann Rheum Dis 72:1771–1776CrossRefGoogle Scholar
  20. 20.
    Lim LSH, Pullenayegum E, Moineddin R et al (2017) Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review and worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatr Rheumatol 15:18CrossRefGoogle Scholar
  21. 21.
    Inanc M (2007) Very early “Rheumatoid” arthritis cohorts: limited by selection. Rheumatology 46:185–187CrossRefGoogle Scholar
  22. 22.
    Hensher M, Price M, Adomakoh S (2006) Referral hospitals. In: Jamison DT, Breman JG, Measham AR (eds) Disease control priorities in developing countries. Oxford University, Washington, DC, pp 1229–1243Google Scholar
  23. 23.
    Hicks KA, Mahaffey KW, Mehran R et al (2018) Standardized definitions for cardiovascular and stroke end point events in clinical trials. Circulation 9:961–972CrossRefGoogle Scholar
  24. 24.
    Gaujoux-Viala C, Mouterde G, Baillet A et al (2012) Evaluating disease activity in rheumatoid arthritis: which composite index is best? A systematic literature analysis of studies comparing the psychometric properties of the DAS, DAS28, SDAI and CDAI. Jt Bone Spine 79:149–155CrossRefGoogle Scholar
  25. 25.
    van Breukelen-van der Stope DF, Van Zeben D, Klop B et al (2016) Marked inderdiagnosis and under treatment of hypertension and hypercholesterolaemia in rheumatoid arthritis. Rheumatology 55:1210–1216CrossRefGoogle Scholar
  26. 26.
    Barber CE, Esdaile JM, Martin LO et al (2016) Gaps in addressing cardiovascular risk in rheumatoid arthritis: assessing performance using cardiovascular quality indicators. J Rheumatol 43:1965–1973CrossRefGoogle Scholar
  27. 27.
    Gossec L, Salejan F, Nataf H et al (2013) Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients. Arthritis Care Res 65:712–717CrossRefGoogle Scholar
  28. 28.
    Dougados M, Soubrier M, Antunex A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international cross-sectional study (COMORA). Ann Rheum Dis 73:62–68CrossRefGoogle Scholar
  29. 29.
    Toms TE, Panoulas VF, Douglas KM et al (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated CV risk? Ann Rheum Dis 69:683–688CrossRefGoogle Scholar
  30. 30.
    Ladak K, Hashim J, Clofford-Rashotte M, Tandon V, Matsos M, Patel A (2018) Cardiovascular risk management in rheumatoid arthritis: a large gap to close. Musculoskelet Care 16:152–157CrossRefGoogle Scholar
  31. 31.
    Bell C, Rowe IF (2011) The recognition and assessment of cardiovascular risk in people with rheumatoid arthritis in primary care: a questionnaire-based study of general practitioners. Musculoskelet Care 9:69–74CrossRefGoogle Scholar
  32. 32.
    Alamao E, Cawston H, Bourdhis F, Al M, Rutten-van Mölken MP, Liao KP (2016) Cardiovascular risk management in patients with AR compared to matched non-RA controls. Rheumatology (Oxford) 55:809–816CrossRefGoogle Scholar
  33. 33.
    Kitas GD, Gabriel SE (2011) Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives. Ann Rheum Dis 70:8–14CrossRefGoogle Scholar
  34. 34.
    van Breukelen-van der Stope DF, Zijlmans J, Van Zeben D et al (2015) Adherence to cardiovascular prevention strategies in patients with rheumatoid arthritis. Scan J Rheumatol 6:443–448CrossRefGoogle Scholar
  35. 35.
    González A, Kremers HM, Crowson CS et al (2008) Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis 67:64–69CrossRefGoogle Scholar
  36. 36.
    Phillips LS, Branch WT, Cook CB et al (2001) Clinical inertia. Ann Intern Med 135:825–834CrossRefGoogle Scholar
  37. 37.
    Ziemer DC, Miller CD, Rhee MK et al (2005) Clinical inertia contributes to poor diabetes control in primary care setting. Diabetes Educ 31:567–571CrossRefGoogle Scholar
  38. 38.
    Lázaro P, Murga N, Aguilar D, Hernández-Presa MA, On Behalf of the INERTIA Study Investigators (2010) Therapeutic inertia in the outpatient management of dyslipidemia in patients with ischemic heart disease. Rev Esp Cardiol 63:1428–1437CrossRefGoogle Scholar
  39. 39.
    Lebeau JP, Cadwallader JS, Aubin-Auger I et al (2014) The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract 15:2–10CrossRefGoogle Scholar
  40. 40.
    Sepheri A, Gil-Guillen VF, Palazón-Bru A et al (2014) Are obese patients assisted in losing weight? Am J Manag Care 20:E122–E128Google Scholar
  41. 41.
    DiBonaventura MD, Meincke H, Le Lay A, Fournier J, Bakker E, Ehrenreich A (2018) Obesity in México: prevalence, comorbidities, associations with patients outcomes and treatment experiences. Diabetes Metab Syndr Obes Targets Ther 11:1–10Google Scholar
  42. 42.
    Cardiel MH, Pons-Estel BA, Sacnun MP et al (2012) Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin-American patients. J Clin Rheumatol 18:327–335CrossRefGoogle Scholar
  43. 43.
    Crowson CS, Rollefstad S, Kitas GD, On Behalf of a Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA) et al (2017) Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis. PLoS One 12:0174656Google Scholar
  44. 44.
    Escalante A, Haas RW, del Rincón I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165:1624–1629CrossRefGoogle Scholar
  45. 45.
    Naranjo A, Sokka T, Descalzo MA et al (2018) Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10:R30CrossRefGoogle Scholar
  46. 46.
    Hainer V, Aldhoon-Hainerova I (2013) Obesity paradox does exist. Diabetes Care 33:S276–S281CrossRefGoogle Scholar
  47. 47.
    Stavropolous-Kalinoglou A, Metsios GS, Panoulas VF et al (2009) Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 68:242–245CrossRefGoogle Scholar
  48. 48.
    Tripepi G, Jager KJ, Dekker FW, Zoccali C (2010) Selection bias and information bias in clinical research. Nephron Clin Pract 115:c94–c99CrossRefGoogle Scholar
  49. 49.
    John H, Hale ED, Bennet P, Treharne GJ, Carrol D, Kitas GD (2011) Translating patient education into practice. Developing material to address the cardiovascular needs of people with rheumatoid arthritis. Patients Educ Couns 1:123–127CrossRefGoogle Scholar
  50. 50.
    Breen GM, Wan TTH, Zhang NJ, Marathe SS, Seblega BK, Paek SC (2009) Improving doctor–patient communication: examining innovative modalities vis-à-vis effective patient-centric care management technology. J Med Syst 33:155–162CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Immunology and RheumatologyInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico

Personalised recommendations